Literature DB >> 26009213

Spondyloarthropathy: interleukin 23 and disease modification.

Jonathan P Sherlock1, Peter C Taylor2, Christopher D Buckley3, Daniel J Cua4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26009213     DOI： 10.1016/S0140-6736(15)60970-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis.

Authors:  Joachim Sieper; Denis Poddubnyy; Pierre Miossec
Journal:  Nat Rev Rheumatol       Date:  2019-09-24       Impact factor: 20.543

Review 2.  A Possible Role of Intestinal Microbiota in the Pathogenesis of Ankylosing Spondylitis.

Authors:  Lianjun Yang; Liping Wang; Xin Wang; Cory J Xian; Hai Lu
Journal:  Int J Mol Sci       Date:  2016-12-17       Impact factor: 5.923

Review 3.  Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross-sectional imaging: a systematic literature review.

Authors:  Jobie Evans; Mark Sapsford; Scott McDonald; Kenneth Poole; Tim Raine; Deepak R Jadon
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-03-11       Impact factor: 5.346

Review 4.  Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis.

Authors:  Angela Ceribelli; Francesca Motta; Matteo Vecellio; Natasa Isailovic; Francesco Ciccia; Carlo Selmi
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

5.  Silencing SOCS3 Markedly Deteriorates Spondyloarthritis in Mice Induced by Minicircle DNA Expressing IL23.

Authors:  Yuhai Chen; Jing Ouyang; Ruoxiang Yan; Mohamed Hassan Maarouf; Xuefei Wang; Biao Chen; Shasha Liu; Jiayue Hu; Guijie Guo; Jing Zhang; Sheng-Ming Dai; Huji Xu; Ji-Long Chen
Journal:  Front Immunol       Date:  2018-11-14       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.